Training & Education

Members of the ACCC IO Institute Executive Committee discuss the importance of tailoring immunotherapy patient education based on the unique needs of each cancer center. (features  David Ettinger, MD, FACP, FCCP; Mark Faries, MD; and Niesha Griffith, MS, RPH, FASHP )

 

As more patients with cancer are treated with immunotherapy and as treatment regimens continue to evolve, the multidisciplinary cancer care team needs ongoing education and training to ensure that patients receive optimal care. To provide the best care possible for patients treated with IO agents, providers need access to timely and relevant education to improve cancer diagnosis and patient selection, the recognition and management of immune-related adverse events (irAEs), and the effective use of survivorship care plans. The IO Training & Education Working Group is composed of multidisciplinary care providers experienced in the delivery of immunotherapy for cancer.

Meet the members of the IO Training & Education Working Group.

Insights from this working group

  • COVID-19 and Patients Receiving Anticancer Immunotherapy
    COVID-19 and Patients Receiving Anticancer Immunotherapy
    By Ryan M. Weight, DO, MS

    SARS-CoV-2 and the resulting respiratory tract infection COVID-19 has upended our society and forcefully changed the way we care for patients. Since the emergence of the virus in early 2020, there have been questions surrounding the risk posed to patients with a cancer diagnosis and the safety of anticancer therapies. 

  • Communication: Key to Addressing Toxicity and Recurrence Risks
    By Mark B. Faries, MD

    Immuno-oncology (IO) has radically altered the patient care paradigm. One of most important changes attributed to IO is improvement in outcomes and lengthening of survival. This good news comes with multiple challenges, not least of which is the need for new and better communication and coordination among multiple specialties over time. 

  • The Oncology Pharmacist's Role in IO Delivery
    By Sarah Hudson-DiSalle, PharmD, RPh

    Are you leveraging the assets of your oncology pharmacists in delivery of immunotherapy for cancer? Oncology pharmacists multidisciplinary team members who help bridge the gap between science and real-world medical practice. Sarah Hudson-DiSalle, PharmD, RPh, describes how your IO program can make the best use of the oncology pharmacist's diverse skillset.  

  • The Intestinal Microbiome and Cancer Immunotherapy
    By Ryan M. Weight, DO, MS

    The human gastrointestinal tract is inhabited by a diverse population of bacteria that play a crucial role in maintaining homeostasis both within the gut and within the body. How much do we know about the gut microbiome as it relates to cancer treatment?  

  • IO Reimbursement: Be Proactive and Prepared
    By Sarah Hudson-DiSalle, PharmD, RPh

    As with other high-cost treatments, integration of immunotherapies into practice requires a thorough understanding of payer policies and requirements for reimbursement. Sarah Hudson-DiSalle, PharmD, RPh, shares key steps for successful reimbursement for cancer immunotherapies.

  • Selecting Patients for Combination Immunotherapies
    By Ryan M. Weight, DO, MS

    A forthright conversation between the treating clinician, patient and family members on the importance of self-reporting adverse events must take place prior to consideration of combination immunotherapy.  

  • IO Trials Are Accruing: Where Are the Patients?
    By Joanne Riemer, RN, BSN

    Research nurse Joannne Riemer, RN, BSN,  started her position at Johns Hopkins Medical Institution in 2010. Within six months, she was working with checkpoint inhibitors. From her vantage point in clinical trials research, she discusses the many changes in IO clinical trials patient selection over the last eight years.